ESTRO 2025 - Abstract Book

S1757

Clinical – Upper GI

ESTRO 2025

Conclusion: MR-guided SBRT for pancreatic oligometastases from RCC appears to be an effective and safe treatment option, achieving excellent long-term local control rates and potentially delay systemic therapy initiation. Treatment was deemed technically successful with consistently high target coverages, even for a large number of simultaneously irradiated lesions. Online adaptive MR-guided SBRT should be considered as a treatment option in the management of pancreatic metastases of RCC patients.

Keywords: MR-guided RT, RCC, pancreatic oligometastases

765

Digital Poster Efficacy and Safety of SBRT for Adrenal Metastases in oligometastatic-disease María del Carmen S Guisasola, Ovidio Hernando-Requejo, Mercedes López, Angel Montero, Bruno zAMBRANA, Beatriz Álvarez, Jaennette Valero, Emilio Sánchez, Carmen Rubio Radiation Oncology, Hospital Universitario HM Sanchinarro, Madrid, Spain Purpose/Objective: Local ablative therapies like SBRT are designed to improve remission rates and long-term outcomes in patients with oligometastatic cancer. While SBRT is well-established for pulmonary and hepatic metastases, its efficacy for adrenal metastases remains underexplored. This study seeks to evaluate the efficacy and safety of SBRT specifically for adrenal metastases in oligometastatic-disease in terms of LC, PFS, OS, treatment-associated toxicity, and prognostic factors.

Material/Methods:

A retrospective analysis was conducted on oligometastatic patients treated with SBRT for adrenal metastases from 2012 to February 2024. Demographic, therapeutic, and dosimetric characteristics were analyzed to assess their effect on outcomes.